Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Current Pharmacogenomics and Personalized Medicine|April 17, 2018
Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A ReviewJesus Rodriguez-Pascual, Antonio Cubillo
Anti-Cancer Drugs|June 21, 2012
Resected duodenal gastrointestinal stromal tumour with an affected margin and exon 9 mutation: adjuvant therapyNuria Rodríguez Salas, Antonio Cubillo
Clinical Orthopaedics and Related Research|March 2, 2005
Intra-articular traumatic disorders of the knee in children and adolescentsJavier Vaquero, Carlos Vidal, Antonio Cubillo
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 17, 2010
Mixed paratesticular liposarcoma with osteosarcoma elementsLisardo Ugidos, Ana Suárez, Antonio Cubillo, et al.
Clinical Lung Cancer|August 8, 2007
Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancerRamón Pérez Carrión, Antonio Cubillo Gracián, Pedro Salinas Hernandez
Surgical Oncology|February 13, 2022
Watch-and-Wait policy versus robotic surgery for locally advanced rectal cancer: A cost-effectiveness study (RECCOSTE)Jesus Rodriguez-Pascual, Javier Nuñez-Alfonsel, Benedetto Ielpo, et al.
BMC Cancer|April 10, 2024
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 studyElena Elez, Antonio Cubillo, Pilar Garcia Alfonso, et al.
Investigational New Drugs|July 21, 2021
Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studiesGeriletu Ao, Maria de Miguel, Ana Gomes, et al.
Future Oncology (London, England)|August 3, 2022
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II studyJohn H Strickler, Antonio Cubillo, Jin-Tung Liang, et al.
Cancers|March 25, 2022
Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II StudyEleni Gkika, Anca-Ligia Grosu, Teresa Macarulla Mercade, et al.
Pageof 6